MKC-442 oral non-nucleoside reverse transcriptase inhibitor data

VIRS announced preliminary Phase Ib/IIa results indicating that MKC-442 reduces the amount of HIV

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE